# A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients

Source: https://onco.cc/trials/nct06522828/  
OnCo record `nct06522828` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of PF-08634404, Carboplatin, Paclitaxel / nab-paclitaxel in endometrial cancer and ovarian cancer, run by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., now recruiting.

## Summary

A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients is a phase 2 interventional study registered as NCT06522828 by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., with 80 participants planned, started 2024-10-10 and due to reach its primary completion in 2025-08. Interventions recorded: SSGJ-707, carboplatin, paclitaxel. Conditions listed: Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06522828
- Phase: 2
- Setting: A Phase 2 Study to Evaluate the Safety and Efficacy of SSGJ-707 in Advanced Gynecologic Cancer Patients
- Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT06522828: https://clinicaltrials.gov/study/NCT06522828

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [PF-08634404](https://onco.cc/drugs/pf-08634404/)

---
JSON: https://onco.cc/api/v1/entities/nct06522828.json